A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer

Cancer

Volumn 107, Issue 2, 2006, Pages 266-274

  Flaig, Thomas W ^a   Barqawi, Albaha ^a   Miller, Gary ^a   Kane, Madeleine ^a   Zeng, Chan ^a   Crawford, E David ^a   Glodé, L Michael ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antineoplastic combined chemotherapy protocols; Carboplatin; Dexamethasone; Human; Male; Metronomic; Prostate neoplasms; Prostate specific antigen; Vitamin D

Indexed keywords

CALCITRIOL; CARBOPLATIN; DEXAMETHASONE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGITATION; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOGENIC SHOCK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLITIS; CONFIDENCE INTERVAL; CONFUSION; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENTERITIS; FATIGUE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCALCEMIA; LEUKOPENIA; MALE; MOON FACE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SEIZURE; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; UNCONSCIOUSNESS; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEXAMETHASONE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; VITAMIN D;

EID: 33745828343     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21982     Document Type: Article

References (46)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis.) Anticancer Res. 1990;10:1307-1311.
3. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992;70:2861-2869.
4. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777-783.
5. Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol. 2000;163:187-190.
6. Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1alpha,25-dihydroxyvitamin D3. Cancer Res. 1992;52:515-520.
7. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25- dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998;139:1197-1207.
8. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology. 2002;143:2508-2514.
9. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha,25- dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 2002;1:667-677.
10. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res. 2001;7:4164-4173.
11. Park WH, Seol JG, Kim ES, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol. 2000;109:576-583.
12. Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 1996;56:264-267.
13. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997;138:1491-1497.
14. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995;136:20-26.
15. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994;54:805-810.
16. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159:2035-2039; discussion, 2039-2040.
17. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001;91:2431-2439.
18. Jungi WF, Bernhard J, Hurny C, et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer. 1998;6:462-468.
19. Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res. 1995;15:2825-2828.
20. Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer. 1993;29A:2094-2096.
21. Trump DL, Marsh JC, Kvols LK, et al. A Phase II trial of carboplatin (NSC 241240) in, advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs. 1990;8(Suppl 1):S91-S94.
22. Qazi R, Khandekar J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1983;6:203-205.
23. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer. 1994;57:847-855.
24. Moffatt KA, Johannes WU, Miller GJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999;5:695-703.
25. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1977;60:253-259.
26. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983;32:151-156.
27. Yu WD, McElwain MC, Modzelewski RA, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 1998;90:134-141.
28. Chen TL, Cone CM, Morey-Holton E, Feldman D. Glucocorticoid regulation of 1,25(OH)2-vitamin D3 receptors in cultured mouse bone cells. J Biol Chem. 1982;257:13564-13569.
29. Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol. 2004;27:535-541.
30. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2:733-740.
31. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
32. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005;23:939-952.
33. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-R24.
34. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98:1643-1648.
35. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
36. Fleming TR. One-sample multiple testing procedure for Phase II clinical trials. Biometrics. 1982;38:143-151.
37. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004;22:537-556.
38. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
39. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
40. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21:123-128.
41. Beer TM, Ryan CW, Venner PM, et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer [abstract 4516]. J Clin Oncol. 2005 2005;23:382s.
42. Nabhan C, Petrylak D, Hussain M, Crawford E. Chemotherapy in advanced prostate cancer. N Engl J Med. 2005;353:200-201.
43. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 1995;76:96-100.
44. Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology. 2002;60:553-561.
45. Saika T, Kusaka N, Tsushima T, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol. 2001;8:290-294.
46. Weitzman AL, Shelton G, Zuech N, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol. 2000;163:834-837.